It was capable of mobilizing hematopoietic stem cells with the CD34 marker, so it has been approved by the US Food and Drug Administration for autologous transplantation of bone marrow cells in patients with non-Hodgkin's lymphoma or multiple myeloma 39-41. The gene discussed is CD34; the disease is non-Hodgkin lymphoma.